Curasight reports first patient dosed in Phase 1 uTREAT trial in brain cancer

Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study

PRISM BioLab partners with Talus Bioscience to address TF and PPI targets

Thryv Therapeutics reports positive Phase 1 results for THRV-1268

Avacta reports tumour shrinkage and 90% disease control rate for AVA6000 in salivary gland cancer patients

Galderma reports data showing rapid itch and sleep improvement with nemolizumab in dermatitis conditions

Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema

Alcami completes third sterile fill-finish line at Research Triangle Park, NC

Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation

Neurocrine Biosciences reveals new chapter in R&D strategy

Nicox completes key data package for NCX 470 NDA submissions

Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II

Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon

Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic

Physiomics secures follow-on UK contract for Phase 2 study support